CME Group (NASDAQ: CME) net income
CME Group reported a net profit of $4,072m for fiscal 2025, 15.5% more than in fiscal 2024 ($3,526m). Its net margin was 62.5%. Earnings per share were $11.18.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $4,072m | +15.5% | 62.5% | $11.18 |
| 2024 | $3,526m | +9.3% | 57.5% | $9.69 |
| 2023 | $3,226m | +19.9% | 57.8% | $8.87 |
| 2022 | $2,691m | +2.0% | 53.6% | $7.41 |
| 2021 | $2,637m | +25.2% | 56.2% | $7.30 |
| 2020 | $2,106m | −0.5% | 43.1% | $5.88 |
| 2019 | $2,117m | +7.9% | 43.5% | $5.93 |
| 2018 | $1,962m | −51.7% | 45.5% | $5.73 |
| 2017 | $4,063m | +164.9% | 111.5% | $12.00 |
| 2016 | $1,534m | — | 42.7% | $4.55 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the net income of CME Group
- How much did CME Group earn in fiscal 2025?
- CME Group reported a net profit of $4,072m for fiscal 2025. In fiscal 2024 it reported a net profit of $3,526m.
- What are the earnings per share of CME Group?
- They were $11.18 in fiscal 2025, compared with $9.69 in fiscal 2024.
- What is the net margin of CME Group?
- In fiscal 2025 its net profit was 62.5% of its revenue.
- What was the most profitable year for CME Group?
- Of its last 10 fiscal years, fiscal 2025, with $4,072m.
- Where do the figures for CME Group come from?
- From the annual report (Form 10-K) that CME Group files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that CME Group files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on CME Group: the CME Group page · annual accounts · revenue · dividends paid · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.